title: Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells.
abstract: Following a description of the way studies of human leukocyte antigen (HLA) class I antigen expression by tumor cells have evolved through the years, the literature related to the frequency of defects in HLA class I antigen processing machinery (APM) component expression in various types of malignancies is reviewed. In addition, the clinical significance of defects in HLA class I APM components as well as the underlying molecular mechanisms are described. Lastly, potential strategies to overcome the defects in HLAclass I APM component expression and function are discussed. The information presented indicates a revival of the interest in the characterization of HLA class I APM component expression by tumor cells since these molecules may play an important role in the outcome of immunotherapy with inhibitory checkpoint molecule-specific monoclonal antibodies in patients with malignant disease. Furthermore, they may represent a useful prognostic biomarker to select patients who might benefit from these types of immunotherapy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Sabbatino
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Schwab
authors.forename: Soldano
authors.initials: S
authors.lastname: Ferrone
authors.forename: Cristina R
authors.initials: CR
authors.lastname: Ferrone
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D017951:Antigen Presentation / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I